↓ Skip to main content

Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies

Overview of attention for article published in Cancer Immunology Research, June 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#9 of 1,271)
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
15 news outlets
twitter
7 tweeters
patent
10 patents

Citations

dimensions_citation
79 Dimensions

Readers on

mendeley
104 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies
Published in
Cancer Immunology Research, June 2015
DOI 10.1158/2326-6066.cir-14-0171
Pubmed ID
Authors

Elizabeth E. Evans, Alan S. Jonason, Holm Bussler, Sebold Torno, Janaki Veeraraghavan, Christine Reilly, Michael A. Doherty, Jennifer Seils, Laurie A. Winter, Crystal Mallow, Renee Kirk, Alan Howell, Susan Giralico, Maria Scrivens, Katya Klimatcheva, Terrence L. Fisher, William J. Bowers, Mark Paris, Ernest S. Smith, Maurice Zauderer

Abstract

Semaphorin 4D (SEMA4D, CD100) and its receptor plexin-B1 are broadly expressed in murine and human tumors, and their expression has been shown to correlate with invasive disease in several human tumors. SEMA4D normally functions to regulate the motility and differentiation of multiple cell types, including those of the immune, vascular, and nervous systems. In the setting of cancer, SEMA4D/PLXNB1 interactions have been reported to affect vascular stabilization and transactivation of ERBB2, but effects on immune cell trafficking in the tumor microenvironment have not been previously investigated. We describe a novel immunomodulatory function of SEMA4D, whereby strong expression of SEMA4D at the invasive margins of actively growing tumors influences the infiltration and distribution of leukocytes in the tumor microenvironment (TME). Antibody neutralization of SEMA4D disrupts this gradient of expression, enhances recruitment of activated monocytes and lymphocytes into the tumor, and shifts the balance of cells and cytokines toward a pro-inflammatory and anti-tumor milieu within the TME. This orchestrated change in the tumor architecture was associated with durable tumor rejection in murine Colon26 and ERBB2+ mammary carcinoma models. The immunomodulatory activity of anti-SEMA4D antibody can be enhanced by combination with other immunotherapies, including immune checkpoint inhibition and chemotherapy. Strikingly, the combination of anti-SEMA4D antibody with antibody to CTLA-4 acts synergistically to promote complete tumor rejection and survival. Inhibition of SEMA4D represents a novel mechanism and therapeutic strategy to promote functional immune infiltration into the TME and inhibit tumor progression.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 104 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Canada 1 <1%
Unknown 102 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 29 28%
Student > Ph. D. Student 18 17%
Student > Doctoral Student 7 7%
Student > Master 6 6%
Other 4 4%
Other 19 18%
Unknown 21 20%
Readers by discipline Count As %
Agricultural and Biological Sciences 22 21%
Medicine and Dentistry 18 17%
Biochemistry, Genetics and Molecular Biology 16 15%
Immunology and Microbiology 11 11%
Unspecified 3 3%
Other 6 6%
Unknown 28 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 121. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 May 2022.
All research outputs
#256,696
of 21,349,333 outputs
Outputs from Cancer Immunology Research
#9
of 1,271 outputs
Outputs of similar age
#3,635
of 321,515 outputs
Outputs of similar age from Cancer Immunology Research
#1
of 29 outputs
Altmetric has tracked 21,349,333 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,271 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 321,515 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.